Stock BMY BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Company Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-18 pm EDT 		5-day change 1st Jan Change
48.3 USD +0.96% Intraday chart for Bristol-Myers Squibb Company -1.67% -5.87%
Apr. 18 Wells Fargo Adjusts Bristol-Myers Squibb's Price Target to $52 From $51, Keeps Equalweight Rating MT
Apr. 17 TORL BioTherapeutics LLC announced that it has received $158.3 million in funding from a group of investors CI

Business Summary

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.

The United States account for 70.1% of net sales.

Number of employees: 34,100

Sales per Business

USD in Million2022Weight2023Weight Delta
Innovative Medicines
100.0 %
46,159 100.0 % 45,006 100.0 % -2.50%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
70.1 %
31,828 69.0 % 31,555 70.1 % -0.86%
International
28.3 %
13,497 29.2 % 12,752 28.3 % -5.52%
Other
1.6 %
834 1.8 % 699 1.6 % -16.19%

Managers

Managers TitleAgeSince
Christopher Boerner CEO
 Chief Executive Officer 53 15-01-31
David Elkins DFI
 Director of Finance/CFO 55 19-11-19
Greg Meyers CTO
 Chief Tech/Sci/R&D Officer - -
Kimberly McCutcheon Jablonski CMP
 Compliance Officer - 02-12-31
Estelle Vester-Blokland CTO
 Chief Tech/Sci/R&D Officer - -
Samit Hirawat CTO
 Chief Tech/Sci/R&D Officer 55 18-12-31
Robert Plenge CTO
 Chief Tech/Sci/R&D Officer 53 19-10-31
Laura Hortas IRO
 Public Communications Contact - -
Cynthia Piccirillo PRN
 Corporate Officer/Principal - -
Cari Gallman PRN
 Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
Phyllis Yale BRD
 Director/Board Member 66 19-11-19
Peter Arduini BRD
 Director/Board Member 59 16-03-31
Derica Rice BRD
 Director/Board Member 59 20-08-31
Paula Price BRD
 Director/Board Member 62 20-08-31
Theodore Samuels BRD
 Director/Board Member 69 17-02-20
David Elkins DFI
 Director of Finance/CFO 55 19-11-19
Christopher Boerner CEO
 Chief Executive Officer 53 15-01-31
Julia Haller BRD
 Director/Board Member 69 19-11-19
Deepak Bhatt BRD
 Director/Board Member 56 22-06-13
Karen Vousden BRD
 Director/Board Member 66 17-12-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 2,928,758,715 2,024,582,731 ( 69.13 %) 902,000,000 ( 30.80 %) 69.13 %

Shareholders

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
9.799 %
198,159,772 9.799 % 10 746 M $
BlackRock Advisors LLC
6.437 %
130,159,802 6.437 % 7 059 M $
JPMorgan Investment Management, Inc.
4.436 %
89,694,867 4.436 % 4 864 M $
STATE STREET CORPORATION
4.423 %
89,446,206 4.423 % 4 851 M $
Capital Research & Management Co. (International Investors)
3.043 %
61,528,492 3.043 % 3 337 M $
Fidelity Management & Research Co. LLC
2.107 %
42,604,966 2.107 % 2 310 M $
Geode Capital Management LLC
1.962 %
39,677,105 1.962 % 2 152 M $
BlackRock Life Ltd.
1.596 %
32,274,031 1.596 % 1 750 M $
Norges Bank (13F)
1.504 %
30,413,639 1.504 % 1 649 M $
Eaton Vance Management
1.452 %
29,362,744 1.452 % 1 592 M $
NameEquities%Valuation
Bram Bradesco Asset Management S/A DTVM
0.000243 %
4,921 0.000243 % 256 847 $
NameEquities%Valuation
Transcend Wealth Collective LLC
-
117,775 - 6 478 $
FourWorld Capital Management LLC
-
100,000 - 5 500 $
Davenport & Co. LLC
-
83,970 - 4 618 $
FIFTH THIRD BANCORP
-
20,000 - 1 100 $
Private Advisor Group LLC
-
15,000 - 825 $
Paradigm Financial Partners LLC
-
10,000 - 550 $
Northwestern Mutual Wealth Management Co.
-
242 - 13 $
OAKWORTH CAPITAL INC.
-
125 - 7 $

Holdings

NameEquities%Valuation
AVIDITY BIOSCIENCES, INC.
6.37%
 5,075,304 6.37% 129,521,758 $
KURA ONCOLOGY, INC.
1.80%
 1,370,171 1.80% 29,225,747 $
UNIQURE N.V.
4.99%
 2,388,108 4.99% 12,418,162 $
COMPUGEN LTD.
5.31%
 4,757,058 5.31% 12,273,210 $
CELULARITY INC.
5.49%
 1,195,327 5.49% 6,251,560 $

Company contact information

Bristol Myers Squibb Co.

Route 206 & Province Line Road

08543, Princeton

+609 252 4621

http://www.bms.com
address Bristol-Myers Squibb Company(BMY)

Group companies

NameCategory and Sector
Bristol-Myers Squibb Pharmaceuticals Ltd.
Logo Bristol-Myers Squibb Pharmaceuticals Ltd.

Bristol-Myers Squibb Pharmaceuticals Ltd.

Pharmaceuticals: MajorHealth Technology

Bristol-Myers Squibb Pharmaceuticals Ltd. manufactures pharmaceutical products. Its products are used for treatment of diseases like cancer, diabetes, arthritis, hepatitis, and psychiatric disorders. The company distributes products throughout the United Kingdom. Bristol-Myers Squibb Pharmaceuticals was founded in 1989 and is located in Uxbridge, UK.

Pharmaceuticals: Major
Celgene Alpine Investment Co. LLC
Bristol-Myers Squibb SARL
Logo Bristol-Myers Squibb SARL

Bristol-Myers Squibb SARL

Medical DistributorsDistribution Services

Bristol-Myers Squibb SARL engages in the research, development, manufacture, and distribution of pharmaceutical products. Its therapeutic areas include immunoscience, immune-oncology, and cardiology. The company is headquartered in Rueil-Malmaison, France.

Medical Distributors
Bristol-Myers Squibb Holdings Ireland Unlimited Co.
Logo Bristol-Myers Squibb Holdings Ireland Unlimited Co.

Bristol-Myers Squibb Holdings Ireland Unlimited Co.

Pharmaceuticals: MajorHealth Technology

Bristol-Myers Squibb Holdings Ireland Unlimited Co., a subsidiary of Bristol Myers Squibb Co., is a company headquartered in Ireland that operates as a holding company which develops medicines for serious diseases.

Pharmaceuticals: Major
Bristol-Myers Squibb Australia Pty Ltd.
Logo Bristol-Myers Squibb Australia Pty Ltd.

Bristol-Myers Squibb Australia Pty Ltd.

Pharmaceuticals: MajorHealth Technology

Bristol-Myers Squibb Australia Pty Ltd. is a biopharmaceutical company that researches, develops and markets medicines for serious diseases. The company was founded in 1930 and is headquartered in Noble Park North, Australia.

Pharmaceuticals: Major
Bristol-Myers Squibb (Finland) Oy Ab
Logo Bristol-Myers Squibb (Finland) Oy Ab

Bristol-Myers Squibb (Finland) Oy Ab

Pharmaceuticals: GenericHealth Technology

Part of Bristol Myers Squibb Co., Bristol-Myers Squibb (Finland) Oy Ab is a Finnish pharmaceutical manufacturing company. The private company is based in Vantaa, Finland. The company was founded in 1974. Simone Böhrer has been the CEO of the company since 2020.

Pharmaceuticals: Generic
Bristol-Myers Squibb Belgium SA
Logo Bristol-Myers Squibb Belgium SA

Bristol-Myers Squibb Belgium SA

Pharmaceuticals: MajorHealth Technology

Part of Bristol Myers Squibb Co., Bristol-Myers Squibb Belgium SA develops, manufactures and distributes medicines. The private company is based in Watermael-Boitsfor, Belgium. The CEO of the Belgian company is Paul Lacante.

Pharmaceuticals: Major
Bristol-Myers Squibb de México S de RL de CV
Logo Bristol-Myers Squibb de México S de RL de CV

Bristol-Myers Squibb de México S de RL de CV

Pharmaceuticals: MajorHealth Technology

Part of Bristol Myers Squibb Co., Bristol-Myers Squibb de México S de RL de CV is a Mexican company that manufactures and supplies pharmaceutical and nutritional products. The private company is located in Mexico.

Pharmaceuticals: Major
Bristol-Myers Squibb AB
Logo Bristol-Myers Squibb AB

Bristol-Myers Squibb AB

Medical DistributorsDistribution Services

Part of Bristol Myers Squibb Co., Bristol-Myers Squibb AB is a private company that wholesales medical equipment and pharmacy. The company is based in Solna, Sweden.

Medical Distributors

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per region

Ratings for Bristol-Myers Squibb Company

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
27
Last Close Price
47.84 USD
Average target price
56.33 USD
Spread / Average Target
+17.74%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
BRISTOL-MYERS SQUIBB COMPANY Stock Bristol-Myers Squibb Company
-5.87% 96.96B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+27.97% 676B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+23.58% 554B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.02% 349B
MERCK & CO., INC. Stock Merck & Co., Inc.
+14.85% 318B
ABBVIE INC. Stock AbbVie Inc.
+6.25% 291B
ASTRAZENECA PLC Stock AstraZeneca PLC
+2.96% 210B
NOVARTIS AG Stock Novartis AG
-0.41% 204B
ROCHE HOLDING AG Stock Roche Holding AG
-10.02% 194B
PFIZER, INC. Stock Pfizer, Inc.
-11.81% 144B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BMY Stock
  4. Company Bristol-Myers Squibb Company